Our study design reflected upon the RCTs performed previously, namely, the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) [33] and the European Randomized Study of Screening for Prostate Cancer (ERSPC) [34]. This evidence concerns the gene KLK3 and prostate cancer.